This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, ...

NRX-100, a preservative-free ketamine, is also under an Abbreviated New Drug Application (“ANDA”) with a priority review ...

--NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced filing for the newly-announced FDA Commissioner's National Priority Voucher program on behalf of NRX-100 ...

Detailed price information for Nrx Pharmaceuticals Inc (NRXP-Q) from The Globe and Mail including charting and trades.

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100) ...

Austin, Texas, United States, June 30th, 2025, FinanceWireThe new FDA voucher program aims to speed approval of drugs aligned with national health priorities.NRX-100, a preservative-free ketamine ...

NRx Pharmaceuticals NRXP, a clinical-stage biopharmaceutical company, and its subsidiary HOPE Therapeutics announced a strategic investor relations partnership with astr partners, a boutique firm ...

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal ...